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Sepsis refers to a systemic inﬂammatory response syndrome resulting from a
microbial infection. The inﬂammatory response is partly mediated by innate
immune cells (such as macrophages, monocytes and neutrophils), which not
only ingest and eliminate invading pathogens but also initiate an inﬂammatory
response upon recognition of pathogen-associated molecular patterns
(PAMPs). The prevailing theories of sepsis as a dysregulated inﬂammatory
response, as manifested by excessive release of inﬂammatory mediators such
as tumour necrosis factor and high-mobility group box 1 protein (HMGB1), are
supported by extensive studies employing animal models of sepsis. Here we
review emerging evidence that support extracellular HMGB1 as a late
mediator of experimental sepsis, and discuss the therapeutic potential of
several HMGB1-targeting agents (including neutralising antibodies and
steroid-like tanshinones) in experimental sepsis.
As a consequence of cohabiting with divergent
microbes (e.g. virus, bacteria and fungi), animals
have to deal with various microbial infections.
Epithelial barriers provide the ﬁrst layer of
defence by limiting the access of potential
pathogens. If they are breached, the host’s innate
immune system mounts an immediate but
nonspeciﬁc biological response – termed
inﬂammation – at the infection site, to conﬁne
and remove invading pathogens. If the invading
pathogens are effectively eliminated,
inﬂammation resolves normally to restore
immunological homeostasis (Ref. 1); however, if
not, invading pathogens or pro-inﬂammatory
mediators such as tumour necrosis factor (TNF)
or other cytokines can leak into the bloodstream,
triggering a systemic inﬂammatory response that
may lead to sepsis (Fig. 1).
Sepsis refers to a systemic inﬂammatory
response syndrome resulting from a microbial
1
Laboratory of Emergency Medicine, The Feinstein Institute for Medical Research, North Shore-LIJ
Health System, Manhasset, NY 11030, USA.
2
Department of Emergency Medicine, North Shore University Hospital – New York University
School of Medicine, Manhasset, NY 11030, USA.
3
Department of Infections Disease, Xiangya Hospital, Central South University, Changsha, Hunan,
P. R. China.
*Corresponding author: Haichao Wang, The Feinstein Institute for Medical Research, North Shore-
LIJ Health System, 350 Community Drive, Manhasset, NY 11030, USA. Tel: +1 516 562 2823;
Fax: +1 516 562 1022; E-mail: hwang@nshs.edu
expert reviews
http://www.expertreviews.org/ in molecular medicine
1
Accession information: doi:10.1017/S1462399408000884; Vol. 10; e32; November 2008
&2008 Cambridge University Press
T
h
e
r
a
p
e
u
t
i
c
p
o
t
e
n
t
i
a
l
o
f
H
M
G
B
1
-
t
a
r
g
e
t
i
n
g
a
g
e
n
t
s
i
n
s
e
p
s
i
sinfection. As a continuum of increasing clinical
severity, ‘severe sepsis’ is deﬁned as sepsis
associated with one or more acute organ
dysfunctions (Ref. 2). Septic shock is severe
sepsis with organ hypoperfusion and
hypotension (deﬁned as systolic blood pressure
less than 90 mmHg) that are poorly responsive
to ﬂuid resuscitation. Despite recent advances in
antibiotic therapy and intensive care, sepsis is
still the most common cause of death in
intensive care units (Ref. 2). Here, we brieﬂy
review the prevailing theories of sepsis as an
uncontrolled systemic inﬂammatory response,
and discuss potential therapeutic agents that
target clinically more feasible, late-acting
mediators of experimental sepsis, such as
HMGB1.
Local innate immune response to
mild infection
Theinnateimmunesystemcomprisesphagocytes
(such as macrophages, monocytes and
neutrophils), mast cells, eosinophils, basophils
and natural killer cells. It constitutes a front line
of defence against most microbial infection by
eliminating invading pathogens and initiating
an inﬂammatory response.
Elimination of invading pathogens
Neutrophils and monocytes continuously patrol
the body to search for invading pathogens, and
inﬁltrate into infected/injured tissues upon
detecting microbial products (Ref. 3). Neutrophils
arrive at the infection site early and in high
numbers, and thus usually kill more invading
A microbial infection can trigger a local or systemic inflammatory response
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Figure 1.Amicrobialinfection can triggeralocal orsystemicinﬂammatory response.Thedisruptionof an
epithelial barrier allows invasion of microbial pathogens, which elicit an innate immune response at the site of
infection.Ifinvadingpathogensareeffectivelyeliminatedbyphagocytes,localinﬂammationresolvesnormallyto
regain immunological homeostasis. If invading pathogens are not effectively eliminated, they can leak into the
bloodstream, and trigger a potentially injurious systemic inﬂammatory response (such as sepsis).
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sbacteria than other phagocytes (Ref. 4). However,
neutrophils are short-lived, with an average
lifespan of 1–2 days: after engulﬁng and killing
several bacteria, neutrophils exhaust intracellular
enzymes and subsequently undergo apoptotic
cell death. Upon reaching extravascular tissues,
monocytes can differentiate into tissue-speciﬁc
macrophages. Macrophages can ingest and
eliminate larger pathogens that are not handled
by the neutrophils; in addition, they remove the
cell debris of apoptotic neutrophils in order to
resolve an inﬂammatory response (Ref. 5).
The recognition of pathogens by phagocytes is
mediated by host bridging proteins called
opsonins (such as complement or antibodies)
(Ref. 6). The speciﬁc recognition of apoptotic
cells is achieved through cell-surface receptors
for phosphatidylserine or opsonins (such as
MFG-E8) (Ref. 7). After binding to these
opsonins, phagocytes engulf pathogens or
damaged cells, and eliminate them through the
generation of reactive oxygen species and
hydrolytic enzymes.
Initiation of the innate inﬂammatory
response
Upon recognition of molecules shared by groups
of related microbes (called pathogen-associated
molecular patterns; PAMPs) by pattern-
recognition receptors (such as the Toll-like
receptors; TLRs), innate immune cells can
initiate an inﬂammatory response. Well-known
PAMPs include bacterial endotoxin
(lipopolysacharides; LPSs), peptidoglycan, and
microbial unmethylated CpG-DNA (Refs 8, 9).
Although there is a structural similarity among
various TLRs, each TLR can recognise a speciﬁc
type of PAMP. For instance, TLR2 is essential
for the recognition of lipoproteins,
peptidoglycan and lipoteichoic acids of most
Gram-positive bacteria (Ref. 10); TLR4
recognises endotoxin of Gram-negative bacteria
(Ref. 11); and TLR9 recognises microbial
unmethylated CpG-DNA (Ref. 8).
Engagement of various TLRs by speciﬁc
PAMPs leads to production and release of
cytokines (such as TNF and the interleukins IL-
1 and IL-6) and chemokines (such as IL-8, and
the ‘macrophage inﬂammatory proteins’ CCL3
and CCL4) (Ref. 12). Chemokines are
responsible for recruiting more innate immune
cells to the site of infection or injury (Ref. 13),
whereas cytokines can activate these immune
cells to produce more pro-inﬂammatory
mediators (Ref. 14). Although an appropriate
inﬂammatory response is required for host
defence against infection, an uncontrolled
systemic inﬂammatory response may contribute
to the pathogenesis of lethal inﬂammation
diseases such as sepsis.
Systemic innate immune response
to severe infection
The prevailing theories of sepsis as an
uncontrolled systemic inﬂammatory response
are supported by extensive studies employing
various animal models of sepsis.
Animal models of experimental sepsis
Experimental sepsis is induced in animals by
three common strategies: infusion of exogenous
bacterial toxin (endotoxaemia); infusion of
exogenous bacteria (bacteraemia); and faecal
contamination of the peritoneal cavity induced
by caecal ligation and puncture (CLP). Each of
these models has particular strengths and
weaknesses with respect to its ability to mimic
the clinical progression of human sepsis (Ref. 15).
Endotoxaemia
Endotoxaemia is induced by intraperitoneal or
intravenous injection of known amounts of
bacterial endotoxin to animals. It provides a
model to investigate pathogenic roles of pro-
inﬂammatory mediators in lethal systemic
inﬂammation. Depending on the doses,
endotoxin can induce transient/nonlethal or
persistent/lethal haemodynamic cardiovascular
responses. Thus, endotoxemia is considered as
a model of septic shock rather than sepsis
(Ref. 15). Other bacterial products (such as
CpG-DNA) can also be used to induce septic
shock in animals.
Bacteraemia
Bacteraemia is induced by intravenous or
intraperitoneal infusion of exogenous viable
bacteria into the host. Because many exogenous
bacteria may not colonise or replicate well in
the host, the doses of bacteria required to
induce lethality do not mimic those inducing a
typical host response to infection in the clinical
setting (Ref. 15). Since various bacteria strains
may induce different cytokine responses, the
bacteraemia model is useful to study the host
response to a particular pathogen.
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sCaecal ligation and puncture
Sepsiscanbeinducedbysurgicalperforationofthe
caecum, a technique known as CLP (Ref. 15). This
procedure allows bacteria spillage and faecal
contamination of the peritoneal cavity, mimicking
the human clinical disease of perforated
appendicitis or diverticulitis. The severity of
sepsis, as reﬂected by the eventual mortality
rates, can be controlled surgically by varying
the size of the needle used for caecal puncture.
CLP in animals induces similar, biphasic
haemodynamic cardiovascular, metabolic and
immunological responses to those observed
during the clinical course of human sepsis.
Thus, the CLP model is considered as the most
clinically relevant model for experimental sepsis.
Inﬂammatory mediators of experimental
sepsis
In response to systemic infection, innate immune
cells release large amounts of pro- and anti-
inﬂammatory mediators that collectively
determinetheoutcomeofsystemicinﬂammation.
Pro-inﬂammatory mediators
Various microbial PAMPs (e.g. LPS and CpG-
DNA) stimulate innate immune cells to release
a wide array of pro-inﬂammatory mediators,
including nitric oxide (Ref. 16), TNF (Ref. 17),
IL-1 (Ref. 18), leukaemia inhibitory factor (LIF)
(Ref. 19), interferon (IFN)-g (Ref. 20), and
macrophage migration inhibitory factor (MIF)
(Refs 21, 22, 23). Extensive studies employing
animal models of sepsis suggest that various
pro-inﬂammatory mediators, individually or in
combination, contribute to the pathogenesis of
lethal systemic inﬂammation. For instance,
neutralising antibodies against bacterial
products (such as endotoxin) (Ref. 24) or an
early pro-inﬂammatory cytokine (TNF; Ref. 17)
reduce lethality in an animal model of
endotoxaemic/bacteraemic shock.
Anti-inﬂammatory mediators
Microbial products also stimulate innate immune
cells to produce anti-inﬂammatory mediators,
such as prostaglandin E2 (PGE2) (Ref. 25), IL-10
(Refs 26, 27) and transforming growth factor
(TGF)-b (Refs 28, 29), which counter-regulate or
suppress potentially injurious pro-inﬂammatory
mediators. Another local feedback mechanism
is through spermine, a ubiquitous biogenic
molecule that accumulates at sites of infection
or injury and post-transcriptionally inhibits
endotoxin-induced release of multiple pro-
inﬂammatory cytokines (e.g. TNF, IL-1b, CCL3
and CCL4) from macrophages and monocytes
(Refs 30, 31, 32, 33). Recent evidence suggests
that the central nervous system can also
attenuate the peripheral innate immune
response through efferent vagus nerve signals
to tissue-resident macrophages (Ref. 34). This
effect is mediated by the principal
neurotransmitter of the vagus nerve,
acetylcholine, which inactivates macrophages
via nicotinic cholinergic receptors (Ref. 34).
Current available therapies for
human sepsis
Currently, available therapies for sepsis are still
limited to several simple clinical interventions:
(1) appropriate broad-spectrum antibiotics; (2)
physiological doses of steroidal anti-
inﬂammatory drugs (e.g. hydrocortisone); (3)
adjunctive therapy with an anticoagulant agent
(e.g. activated protein C); (4) early goal-directed
therapies (EGDTs) to restore tissue oxygen
delivery; and (5) intensive insulin therapy to
regain normoglycaemia (Table 1).
Antibiotics
Once the infecting agents are identiﬁed,
appropriate broad-spectrum antibiotics are
immediately administered to patients to
facilitate elimination of bacterial pathogens
(Ref. 2). However, administration of antibiotics
may also trigger release of bacterial products
(such as endotoxin or CpG-DNA) that may
further stimulate innate immune cells to release
pro-inﬂammatory cytokines. Thus, anti-
inﬂammatory agents may be useful to
pharmacologically modulate a potentially
injurious inﬂammatory response.
Steroidal anti-inﬂammatory drugs
Steroidal anti-inﬂammatory drugs refer to a
group of steroid-like molecules that can reduce
an inﬂammatory response. Although high-dose
steroid (e.g. methylprednisolone at 30 mg/kg or
dexamethasone at 0.5 mg/kg body weight/day)
was harmful to septic patients (Ref. 35), one
study showed low-dose steroid therapy (50 mg
hydrocortisone every 6 h, plus 50 mgo r a l
ﬂudrocortisone for 7 days) was beneﬁcial for
septic patients with adrenal insufﬁciency (i.e.
poor endogenous responses to steroid-inducing
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shormones) (Ref. 36). However, a more recent
multicentre clinical trial indicated that
intravenous hydrocortisone (50 mg every 6 h for
5 days) did not improve 28-day survival of
patients with septic shock, regardless of
whether patients were responsive or
nonresponsive to steroid-inducing hormones
(corticotrophin) (Ref. 37). It raises the question
of whether the dose and the timing of an
anti-inﬂammatory agent are critical for the
successful management of human sepsis (Ref. 2).
Activated protein C
The systemic inﬂammatory response is integrally
related to intravascular coagulation and
endothelial activation. As a major regulator of
haemostasis, thrombin has both pro- and anti-
coagulant properties. The procoagulant
activities of thrombin include proteolytic
activation of blood-clotting factors (Va, VIIIa
and XI), cleavage of ﬁbrinogen to form a ﬁbrin
clot, and stimulation of platelet aggregation.
The anticoagulant effect of thrombin is
regulated by thrombomodulin, a cofactor that is
expressed on the luminal surface of vascular
endothelium. Following engagement of
thrombin to thrombomodulin, the ability of
thrombin to catalyse procoagulant reactions is
inhibited, but its ability to activate a plasma
anticoagulant, activated protein C, is enhanced
.1000-fold, which results in inactivation of
blood clotting factors. In a large clinical trial,
human recombinant activated protein C
(drotrecogin alfa) reduced 28-day mortality
(from 30.8% in the placebo group to 24.7% in
the experimental group) (Ref. 38), but was
accompanied by a 1.5% increase in
haemorrhagic complication risk (Ref. 38). Thus,
activated protein C has been approved by the
US Food and Drug Administration only for
patients with severe sepsis, who are more likely
to die if otherwise not treated.
In addition to activated protein C, other
anticoagulation agents, such as tissue factor
pathway inhibitor and antithrombin III, have
also been tested in clinical sepsis trials.
Although both these agents were beneﬁcial in
preclinical studies or Phase I or II clinical trials,
they failed to reduce 28-day mortality rates in
Phase III clinical trials (Refs 39, 40).
Early goal-directed therapies
As a supportive treatment, EGDT employs
extremely tight control of several physiological
parameters (such as central venous pressure,
mean arterial blood pressure, central venous
oxygen saturation, and haematocrit) with
discrete interventions of crystalloid ﬂuid,
vasopressors and blood transfusions. In a
controlled, randomised, prospective clinical
trial, EGDT – combining volume resuscitation,
catecholamine therapy and transfusion –
effectively reduced mortality rates of patients
with septic shock (from 46.5% in the placebo
group to 30.5% in the experimental group)
(Ref. 41). While achieving a signiﬁcant
reduction in mortality through relatively simple
interventions, this approach is labour intensive,
requiring intensive and continuous staff
commitment (Ref. 42). Furthermore, a recent
multicentre clinical trial indicated that low-dose
vasopressin (0.01–0.03 U/min) alone did not
signiﬁcantly reduce the 28-day mortality rate of
patients with septic shock (35.4% in the
vasopressin group versus 39.3% in the
noradenaline control group; P ¼ 0.26) (Ref. 43).
Table 1. Current available therapies for sepsis
Therapies Agents Ref.
Antimicrobial Broad-spectrum antibiotics to facilitate pathogen elimination 2
Anti-inﬂammatory Hydrocortisone and ﬂudrocortisones to attenuate excessive
inﬂammatory response
36
Anticoagulant Activated protein C to prevent blood clotting 38
Tight control of physiological
parameters
Early goal-directed therapy (resuscitation with crystalloid ﬂuid;
vasopressor;bloodtransfusion)tominimiseglobaltissuehypoxia
41
Antihyperglycaemia Insulin to maintain normal blood glucose levels 44
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In critically ill patients, hyperglycaemia
frequently occurs, and this has long been
perceived as a beneﬁcial metabolic response to
stress that ensures glucose supply to insulin-
insensitive organs (such as the brain and the
immune system). However, this notion has
recently been challenged by two landmark
publications revealing that tight blood glucose
control with intensive insulin therapy
signiﬁcantly improved morbidity and mortality
in critical ill septic patients (Refs 44, 45).
Nevertheless, the zeal for infusing insulin
has been tempered by the announcement of
unsuccessful multicentred clinical trials (Ref. 46).
HMGB1 as a novel therapeutic target
for experimental sepsis
TheearlykineticsofsystemicTNFaccumulationin
sepsis makes it a difﬁcult therapeutic target in
clinical settings (Ref. 17), prompting a search for
other, late pro-inﬂammatory mediators that may
offer a wider therapeutic window. Here we brieﬂy
review evidence that supports extracellular
HMGB1 as a potential novel therapeutic target.
Intracellular HMGB1 as a DNA-binding
protein
HMGB1 is constitutively expressed in many cell
types, and a large ‘pool’ of preformed HMGB1
is stored in the nucleus as a result of the
presence of two lysine-rich nuclear localisation
sequences (Refs 47, 48). It contains two internal
repeats of positively charged domains (‘HMG
boxes’ known as the ‘A box’ and ‘B box’) in the
N-terminus, and a continuous stretch of
negatively charged (aspartic and glutamic acid)
residues in the C-terminus. The HMG boxes
enable HMGB1 to bind chromosomal DNA and
fulﬁl its nuclear functions, including
determination of nucleosomal structure and
stability,andregulationofgeneexpression(Ref.49).
Extracellular HMGB1 as an alarmin signal
Recently, a number of structurally diverse,
multifunctional, ubiquitous host proteins – such
as HMGB1 and heat shock protein 72 (HSP72) –
have been categorised as ‘alarmins’ based on the
following shared properties (Ref. 50) (Fig. 2).
Active release and passive leakage
Inresponsetoexogenousbacterialproducts(such
as endotoxin or CpG-DNA) (Refs 51, 52) or
endogenous inﬂammatory stimuli (e.g. TNF,
IFN-g or hydrogen peroxide) (Refs 51, 53, 54),
innate immune cells actively release HMGB1 in
a dose- and time-dependent manner (Fig. 2).
Lacking a leader signal sequence, HMGB1
cannot be actively secreted via the classical
secretory pathway from the endoplasmic
reticulum through the Golgi complex (Ref. 51).
Instead, activated macrophages/monocytes
acetylate HMGB1 at its nuclear localisation
sequences, leading to sequestration of HMGB1
within cytoplasmic vesicles and subsequent
extracellular release (Refs 48, 53, 55). In
addition, HMGB1 can be released passively
from damaged cells (Ref. 56) or cells infected by
viruses (e.g. West Nile virus, Salmon anaemia
virus, and Dengue virus) (Refs 57, 58, 59), and
such HMGB1 similarly triggers an
inﬂammatory response (Ref. 60) (Fig. 2).
Stimulation of cell migration
Accumulating evidence indicates that HMGB1
can stimulating migration of neurites (Ref. 61),
smooth muscle cells (Ref. 62), tumour cells
(Ref. 63), mesoangioblast stem cells (Refs 64,
65), monocytes (Ref. 66), dendritic cells (Refs 67,
68) and neutrophils (Ref. 69) (Fig. 2). It raises a
possibility that extracellular HMGB1 may
recruit cells to sites of infection or injury
(Ref. 62), thereby functioning as a potential
chemokine (Ref. 70).
Facilitation of innate recognition
of microbial products
Recent studies suggested that HMGB1 can
facilitate recognition of bacterial products (e.g.
CpG-DNA or LPS) by innate immune cells
(such as macrophages and dendritic cells)
(Refs 52, 71, 72) (Fig. 2). For instance,
extracellular HMGB1 can bind to biologically
active microbial CpG-DNA, and facilitate its
innate recognition by the intracellular TLR9
receptor, thereby augmenting CpG-DNA-
induced inﬂammatory responses (Refs 52, 71).
Activation of innate immune cells
ExtracellularHMGB1bindstoseveralcell-surface
receptors, including the receptor for advanced
glycation end products (RAGE), and pattern-
recognition receptors such as TLR2 and TLR4
(Refs 73, 74). Consequently, HMGB1 activates
innate immune cells (Refs 73, 74, 75, 76, 77) or
endothelial cells (Refs 78, 79) to produce pro-
inﬂammatory cytokines, chemokines and
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of HMGB1 functions as an antagonist of HMGB1
(Refs 80, 81), whereasthe ‘B box’ recapitulates the
cytokine activity of full-length HMGB1 (Refs 82,
83).
In vitro, exogenous HMGB1 appears to
accumulate on the macrophage cell surface
within 4–6 h of HMGB1 incubation (Ref. 84),
which correlates with the kinetics of HMGB1-
induced release of pro-inﬂammatory cytokines
(Ref. 85). It is not yet known whether
engagement of exogenous HMGB1 to cell-
surface receptors (such as TLR2, TLR4 or
RAGE) induces cell-surface clustering of
ligand–receptor complexes (Ref. 84), thereby
activating various innate immune cells.
In the brain, exogenous HMGB1 induces the
release of pro-inﬂammatory cytokines (Ref. 86)
and excitatory amino acids (such as glutamate)
(Ref. 87), induces fever (Ref. 88), and exacerbates
cerebral ischaemic injury (Ref. 89). In the lung,
HMGB1 induces neutrophil inﬁltration and acute
injury (Refs 90, 91, 92). Considered together, these
studies indicate that extracellular HMGB1 can
Extracellular HMGB1 functions as an alarmin signal
Expert Reviews in Molecular Medicine © 2008 Cambridge University Press
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Figure2.ExtracellularHMGB1functionsasanalarminsignal.HMGB1isactivelysecretedbyinnateimmune
cells in response to exogenous bacterial products (e.g. endotoxin or CpG-DNA) or endogenous inﬂammatory
stimuli (e.g. TNF, IFN-g or hydrogen peroxide), and passively released by damaged or virus-infected cells.
Extracellular HMGB1 sustains an inﬂammatory response by stimulating migration of innate immune cells,
facilitating innate recognition of bacterial products (e.g. CpG by TLR9 and endotoxin by TLR4), activating
various innate immune cells, and inhibiting phagocytosis of apoptotic neutrophils. Thus, HMGB1 can
function as an alarmin signal, which recruits, alerts and activates various innate immune cells, thereby
sustaining a potentially injurious inﬂammatory response. Abbreviations: HMGB1, high-mobility group box 1
protein; IFN-g interferon, g; TLR, Toll-like receptor; TNF, tumour necrosis factor.
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activate innate immune cells, thereby sustaining a
potentially injurious inﬂammatory response.
Inhibition of phagocytotic elimination
of apoptotic neutrophils
As mentioned above, macrophages recognise
apoptotic cells through cell-surface receptors for
phosphatidylserine. Interestingly, a recent study
indicated that HMGB1 could interact with
phosphatidylserine on the cell surface of
apoptotic neutrophils, and consequently inhibit
phagocytotic elimination of apoptotic
neutrophils by macrophages (Ref. 93). Impaired
clearance of apoptotic cells may allow excessive
accumulation of late apoptotic and/or secondary
necrotic cells, which may directly (Ref. 94), or
indirectly (by activating phagocytes), release
pro-inﬂammatory mediators (such as HMGB1)
(Ref. 95). Thus, extracellular HMGB1 may
sustain rigorous inﬂammatory responses by
multiple mechanisms including interference
with phagocytotic elimination of apoptotic
neutrophils (Ref. 93) (Fig. 2).
Pathogenic role of HMGB1 in diseases
Accumulating evidence has supported a
pathogenic role for extracellular HMGB1 in
infection-orinjury-elicitedinﬂammatorydiseases.
Experimental sepsis
In murine models of endotoxaemia and sepsis
(induced by CLP), HMGB1 is ﬁrst detectable in
the circulation 8 h after the onset of lethal
endotoxaemia and sepsis, subsequently
increasing to plateau levels from 16 to 32 h
(Refs 51, 80). This late appearance of circulating
HMGB1 precedes and parallels the onset of
animal lethality from endotoxaemia or sepsis,
and distinguishes HMGB1 from TNF and other
earlyproinﬂammatorycytokines(Ref.96)(Fig.3).
The pathogenic role of HMGB1 as a late
mediator of lethal endotoxaemia was originally
examined using HMGB1-speciﬁc neutralising
antibodies, which conferred a dose-dependent
protection against lethal endotoxaemia (Ref. 51)
and endotoxin-induced acute lung injury
(Ref. 90). In a more clinically relevant animal
model of sepsis (induced by CLP), delayed
administration of HMGB1-speciﬁc neutralising
antibodies beginning 24 h after the onset of
sepsis, rescued mice from lethal sepsis in a dose-
dependent manner (Refs 80, 95). Similarly, anti-
HMGB1 antibodies conferred protection in a rat
model of sepsis (induced by CLP) (Ref. 97). In
contrast, administration of exogenous HMGB1 to
mice recapitulates many clinical signs of sepsis,
including fever (Ref. 88), derangement of
intestinal barrier function (Ref. 98), and tissue
injury (Refs 90, 91). Taken together, these
experimental data establish extracellular HMGB1
as a critical late mediator of experimental sepsis,
with a wider therapeutic window than early
pro-inﬂammatory cytokines (Fig. 3).
Ischaemic tissue injury
By contrast to the delayed systemic HMGB1
accumulation in experimental sepsis, HMGB1
Early versus late mediators of 
septic lethality
Expert Reviews in Molecular Medicine 
© 2008 Cambridge University Press
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246 1234
HMGB1
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Late mediators (>24 h)
Early mediators
Therapeutic windows
TNF
Hours Days
Figure 3. Early versus late mediators of septic
lethality. Vertebrates subjected to septic insult
succumb at latencies of up to several days, long
after serum TNF has returned to basal levels. By
contrast to early pro-inﬂammatory cytokines,
systemic HMGB1 accumulation occurs in a
delayed fashion, which precedes and parallels the
onset of septic lethality (Refs 96, 146). This
delayed systemic accumulation makes HMGB1 a
better therapeutic target with a wider therapeutic
window for experimental sepsis. CLP, caecal
ligation and puncture; HMGB1, high-mobility
group box 1 protein; IFN-g, interferon g; TNF,
tumour necrosis factor.
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sfunctions as an early mediator of ischaemia–
reperfusion (I–R) injury (Refs 99, 100, 101, 102).
Prophylactic administration of HMGB1-speciﬁc
neutralising antibody conferred signiﬁcant
protection against hepatic I–R injury in wild-
type mice, but not in a TLR4-defective (C3H/
HeJ) mutant, implicating TLR4 in HMGB1-
mediated hepatic I–R injury (Ref. 99). Similarly,
treatment with HMGB1 antagonist (such as
HMGB1 box A) signiﬁcantly reduced
myocardial ischaemic injury in wild-type mice,
but in this case not in RAGE-deﬁcient mutants,
indicating a potential role for RAGE in
HMGB1-mediated ischaemic injury (Ref. 103).
In addition, HMGB1-speciﬁc neutralising
antibodies have been proven protective against
ventilator-induced acute lung injury (Ref. 104),
severe acute pancreatitis (Ref. 105), and
haemorrhagic shock (Ref. 106), supporting a
pathogenic role for extracellular HMGB1 in
various inﬂammatory diseases. However,
HMGB1 is capable of attracting stem cells
(Ref. 64), and may be important for tissue repair
and regeneration. Therefore, like other cytokines,
extracellular HMGB1 may have protective roles
when released at low amounts (Ref. 107). It is
thus important to pharmacologically modulate,
rather than abrogate, systemic HMGB1
accumulation to facilitate resolution of a
potentially injurious inﬂammatory response.
Otherpro-inﬂammatorymediatorsofsepsis
In addition to HMGB1, other pro-inﬂammatory
mediators (such as complement anaphylatoxin,
C5a and MIF) also accumulate in the circulation
in sepsis (Refs 21, 22, 23, 108), and contribute to
the pathogenesis of sepsis. For instance,
blockade of MIF with neutralising antibodies as
late as 8 h after onset of experimental sepsis
improved survival in mice (Ref. 22). Similarly,
blockade of C5a or its cell-surface receptors
(C5aR or C5L2) with speciﬁc neutralising
antibodies protects animals against lethal sepsis
(Refs 108, 109, 110), supporting a role for C5a in
the pathogenesis of sepsis. Intriguingly, C5L2
may play an important role in the regulation of
HMGB1 release, because HMGB1 release was
somewhat impaired in C5L2-deﬁcient mice
following septic insult, and C5L2-deﬁcient
peritoneal macrophages following LPS
stimulation (Ref. 110). Thus, many known (such
as HMGB1, C5a and MIF) or as yet unidentiﬁed
pro-inﬂammatory mediators may synergistically
interact with each other and collectively
contribute to the pathogenesis of sepsis.
NovelHMGB1-targetingtherapeuticagents
With a limited number of effective therapies
available for patients with sepsis, it is important
to search for other agents capable of inhibiting
clinically accessible late mediators, such as
HMGB1. As discussed below, several agents
have been proven protective against
experimental sepsis partly through attenuating
systemic HMGB1 accumulation (Table 2).
Anticoagulant agents
Antithrombin III
Although antithrombin III failed to reduce
mortality rate in a large sepsis clinical trial
(Ref. 40), a recent study suggested that
antithrombin III could attenuate endotoxin-
induced systemic HMGB1 accumulation, and
reduced endotoxaemic lethality (Ref. 111). The
mechanisms by which antithrombin III, a liver-
derived anticoagulant glycoprotein, inhibits
HMGB1 release remain to be investigated.
Thrombomodulin
As mentioned above, another anticoagulant
molecule, thrombomodulin, can interact with
thrombin to activate protein C. Interestingly,
human soluble thrombomodulin (ART-123) can
physically bind to HMGB1 protein, thereby
inhibiting an HMGB1-mediated inﬂammatory
response. Indeed, ART-123 conferred signiﬁcant
protection against lethal endotoxaemia partly by
attenuating HMGB1-mediated inﬂammatory
response (Ref. 112). It is not yet known, however,
whether ART-123 confers similar protection in
more clinically relevant animal models of sepsis.
Danaparoid sodium
A third anticoagulant, danaparoid sodium, also
prevents blood clotting by inactivating thrombin.
It is often used for individuals who cannot be
given heparin because of heparin-induced
thrombocytopaenia. Intriguingly, danaparoid
sodium effectively protected rats against
endotoxin-inducedacutelunginjurybyattenuating
systemicHMGB1accumulation(Ref.113).
Intravenous immunoglobulin
Intravenous immunoglobulin(IVIG) referstoIgG
immunoglobulins (antibodies) pooled from the
plasma of many healthy blood donors. It is
expert reviews
http://www.expertreviews.org/ in molecular medicine
9
Accession information: doi:10.1017/S1462399408000884; Vol. 10; e32; November 2008
&2008 Cambridge University Press
T
h
e
r
a
p
e
u
t
i
c
p
o
t
e
n
t
i
a
l
o
f
H
M
G
B
1
-
t
a
r
g
e
t
i
n
g
a
g
e
n
t
s
i
n
s
e
p
s
i
susually given intravenously as a plasma protein
replacement therapy to patients with various
inﬂammatory diseases due to acute infections,
autoimmune disease, or immune deﬁciencies.
A recent study indicated that IVIG dose-
dependently protected rats against sepsis-
induced lung injury and lethality by
attenuating systemic HMGB1 release (Ref. 114).
The mechanisms by which IVIG suppresses
systemic HMGB1 release remain poorly
understood. Notably, it has recently been found
that human IgGs can bind to HMGB1, and
potentially interfere with ELISA detection of
HMGB1 (Ref. 115). It is thus important to ask
whether IVIG indeed attenuates systemic
HMGB1 accumulation, or simply interferes
with ELISA detection of HMGB1 in serum
samples.
Endogenous hormones
Insulin
A recent study indicated that hyperglycaemia,
induced by infusion of glucose immediately
following endotoxaemia, aggravated endotoxin-
Table 2. Potential therapeutic agents for experimental sepsis
Therapeutic agents Protects against Partly by Refs
Anticoagulant agents
Antithrombin III LPS-induced lethality # HMGB1 release? 111
Thrombomodulin LPS-induced lethality # HMGB1 activity 112
Danaparoid sodium LPS-induced lung injury and lethality # HMGB1 release 113
Endogenous hormones
Insulin LPS-induced lung injury and lethality # HMGB1 release? 116, 117
VIP CLP-orbacteraemia-inducedlethality # HMGB1 release 118
PACAP LPS-induced lethality # HMGB1 release 119
Urocortin CLP-orbacteraemia-inducedlethality # HMGB1 release 118
Ghrelin CLP-induced lung injury and lethality # HMGB1 release 120, 122
" Pathogenelimination
Vagus nerve stimulation
Electrical LPS or CLP-induced lethality # HMGB1 release 125
Chemical(nicotineorGTS-21) LPS or CLP-induced lethality # HMGB1 release 127, 128
Mechanical (transcutaneous) LPS or CLP-induced lethality # HMGB1 release 126
Neutralising antibodies LPS or CLP-induced lethality # HMGB1 activity 80, 97
Intravenous
immunoglobulin
CLP-induced lung injury and lethality # HMGB1 release? 114
Stearoyl LPC LPS or CLP-induced lethality # HMGB1 release 47, 130
" Pathogenelimination 129
Ethyl pyruvate LPS or CLP-induced lethality # HMGB1 release 132
Chinese herbal
components
Danshen (TSN IIA-SS) LPS or CLP-induced lethality # HMGB1 release 135
Green tea (EGCG) LPS or CLP-induced lethality # HMGB1 release 84
# HMGB1 activity 84
Abbreviations:CLP,cecalligationandpuncture;EGCG,epigallocatechin3-gallate;HMGB1,high-mobilitygroup
box 1; IVIG, Intravenous immunoglobulin; LPC, lysophosphatidylcholine; LPS, lipopolysaccharide; PACAP ,
pituitary adenylate cyclase-activating polypeptide; TNS IIA-SS, tanshinone IIA sodium sulphonate; VIP ,
vasoactive intestinal peptide.
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(Ref. 116). By contrast, intensive blood
glucose control by insulin conferred protection
against endotoxin-induced acute lung injury, and
endotoxaemic lethality (Ref. 116). It is currently
unknown whether the observed protective
effects are dependent on insulin’s anti-
inﬂammatory activities or its blood-glucose-
modulating properties (Ref. 117).
Neuropeptides
Vasoactiveintestinalpeptide(VIP)isashort-lived
small peptide hormone that is produced by the
gut, pancreas and brain. It can induce smooth
muscle relaxation, and is involved in
communication between brain neurons. In
animal models of sepsis induced by CLP or
bacteraemia, administration of VIP attenuated
systemic HMGB1 accumulation, and
consequently reduced animal lethality
(Ref. 118). Consistently, replenishing septic
animals with recombinant HMGB1 completely
reversed VIP-mediated protective effects
(Ref. 118), conﬁrming a pathogenic role for
HMGB1 in experimental sepsis.
AnothermemberoftheVIPfamily,thepituitary
adenylate cyclase-activating polypeptide
(PACAP), shares 68% amino acid sequence
identity with VIP. It is abundantly expressed in
the central and peripheral nervous systems, and
functions as a parasympathetic and sensory
neurotransmitter. Interestingly, administration
of PACAP peptide also signiﬁcantly attenuated
circulating HMGB1 levels, and similarly
protected mice against lethal endotoxaemia
(Ref. 119).
The neuropeptide urocortin, which belongs to
the corticotropin-releasing factor family, is
expressed in the brain and may be responsible for
regulation of appetite. In animal models of sepsis
induced by CLP or bacteraemia, administration
of urocortin attenuated systemic HMGB1
accumulation and reduced animal lethality
(Ref. 118), supporting a therapeutic potential
for neuropeptides in experimental sepsis.
Ghrelin
Ghrelin is a stomach-derived hormone that is
responsible for regulating the appetite –
increasing it before eating and decreasing it
afterwards. Intriguingly, plasma ghrelin levels
are signiﬁcantly decreased in septic animals
(Ref. 120), and administration of ghrelin
promoted a dose-dependent protection against
sepsis-induced acute lung injury and lethality
(Refs 120, 121, 122). Ghrelin may exert its
protective effects through multiple mechanisms,
such as by attenuating systemic HMGB1 release
and by facilitating bacterial elimination
(Ref. 122). Intriguingly, ghrelin may attenuate
systemic accumulation of pro-inﬂammatory
cytokines partly via the vagus nerve (Ref. 121),
suggesting that pharmacological stimulation of
the vagus nerve may be an effective therapy for
experimental sepsis.
Vagus nerve stimulation
The vagus nerve is the structural basis for the
cholinergic anti-inﬂammatory pathway
(Ref. 123), which inhibits the innate immune
response via the release of acetylcholine.
Acetylcholine binds to a7 nicotinic acetylcholine
receptors of various innate immune cells
(Ref. 124), thereby counter-regulating potentially
injurious innate immune responses. Indeed,
stimulation of the vagus nerve by physical
methods (e.g. electrical or mechanical) (Refs 125,
126) or chemical agents (such as the cholinergic
agonists nicotine and GTS-21) (Refs 127, 128)
conferred protection against lethal endotoxaemia
and sepsis partly by attenuating systemic
HMGB1 accumulation.
Stearoyl lysophosphatidylcholine
An endogenous phospholipid, stearoyl
lysophosphatidylcholine (LPC), has recently
been proven protective against experimental
sepsis by stimulating neutrophils to destroy
ingested bacteria in a mechanism dependent on
hydrogen peroxide (Ref. 129). However, stearoyl
LPC also confers protection against lethal
endotoxaemia (Ref. 129), implying that it may
exert protective effects through an additional,
bactericidal-independent mechanism (Ref. 130).
Indeed, administration of stearoyl LPC
signiﬁcantly attenuated circulating HMGB1
levels (Ref. 47), indicating that stearoyl LPC
protects against experimental sepsis partly by
facilitating elimination of invading pathogens
and partly by attenuating systemic HMGB1
accumulation (Ref. 130).
Ethyl pyruvate
Ethyl pyruvate is an aliphatic ester derived from
pyruvicacid,whichisaﬁnalproductofglycolysis
and the starting substrate for the tricarboxylic
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sacid cycle (Ref. 131). It dose-dependently
inhibits LPS-induced release of early (e.g. TNF)
and late (e.g. HMGB1) pro-inﬂammatory
cytokines, and protected mice against
experimental sepsis even when treatment was
started as late as 12–24 h after the onset of
disease (Ref. 132).
Chinese medicinal herbs
Traditional herbal medicine has formed the basis
of folk remedies for various inﬂammatory
ailments. Out of several dozen commonly used
Chinese herbs (Ref. 133), we found that
aqueous extracts of danggui (Angelica sinensis),
green tea (Camellia sinensis), and danshen (Salvia
miltorrhiza) efﬁciently inhibited endotoxin-
induced HMGB1 release, and protected
animals against experimental sepsis (Refs 84,
134, 135).
Danggui
Danggui has been traditionally used to treat
gynaecological disorders (such as abnormal
menstruation) (Ref. 136). Its aqueous extract dose-
dependently inhibited LPS-induced HMGB1
release in macrophage and monocyte cultures,
partly by interfering with HMGB1 cytoplasmic
translocation (Ref. 134). Furthermore, danggui
extract rescued mice from lethal sepsis even
w h e nt h eﬁ r s td o s ew a sg i v e na t2 4ha f t e ro n s e t
o fd i s e a s e( R e f .1 3 4 ) .T h ea c t i v ec o m p o n e n t s
responsible for these beneﬁcial effects remain a
subject of future investigation.
Green tea
Green tea brewed from the leaves of Camellia
sinensis contains a class of biologically active
polyphenols called catechins. Epigallocatechin
3-gallate (EGCG), which accounts for 50–80%
of the total catechin, is effective in attenuating
endotoxin-induced HMGB1 release by
macrophage and monocytes (Ref. 84). In
addition, EGCG dose-dependently inhibited
HMGB1-induced release of TNF, IL-6 and nitric
oxide in macrophage cultures (Ref. 84).
Interestingly, EGCG completely abrogated
accumulation/clustering of exogenous HMGB1
on the macrophage cell surface (Ref. 84),
suggesting that EGCG inhibits HMGB1
cytokine activities by preventing its cell-surface
accumulation/clustering.
In vivo, repeated administration of EGCG
conferred a dose-dependent protection against
lethal endotoxaemia, and rescued mice from
lethal sepsis even when the ﬁrst dose of EGCG
was given at .24 h after onset of sepsis (Ref. 84).
Consistently, delayed administration of EGCG
signiﬁcantly attenuated circulating levels of
HMGB1, as well as surrogate markers of
experimental sepsis (such as IL-6 and chemokine
KC) (Refs 84, 137). Considered together, these
experimental data indicate that EGCG protects
mice against lethal sepsis partly by attenuating
systemic HMGB1 accumulation, and partly by
inhibiting HMGB1-mediated inﬂammatory
response.
Danshen
Danshen has been widely used in China for
patients with cardiovascular disorders (Refs 138,
139). Danshen contains abundant red pigments
(termed tanshinone I, tanshinone IIA, and
cryptotanshinone) (Fig. 4), which effectively
attenuated LPS-induced HMGB1 release
(Ref. 135). A water-soluble derivative (sodium
sulphonate) of tanshinone IIA (TSN IIA-SS)
at concentrations (100 mM) that completely
abrogated LPS-induced HMGB1 release, only
partially attenuated LPS-induced release of four
out of 62 cytokines (IL-12p70, IL-1a, platelet
factor 4 and CCL12) (Ref. 135), indicating a
speciﬁcity for TSN IIA-SS in inhibiting LPS-
induced HMGB1 release. Despite a structural
resemblance (i.e. the presence of a fused four-
ring structure) between tanshinones and
steroidal anti-inﬂammatory drugs (such as
dexamethasone and cortisone) (Fig. 4),
tanshinones inhibit LPS-induced HMGB1-
release in a glucocorticoid-receptor-independent
mechanism (Ref. 135).
More importantly, repeated administration of
TSN IIA-SS, beginning at .24 h and followed
by additional doses at .48, .72 and .96 h
after the onset of sepsis, dose-dependently
rescued mice from lethal sepsis (Ref. 135).
Notably, administration of TNS IIA-SS dose-
dependently attenuated circulating HMGB1
levels in septic mice (Ref. 135), suggesting that
TSN IIA-SS confers protection against
experimental sepsis partly by inhibiting
systemic HMGB1 accumulation.
Clinical implications
Forcomplexsystemicinﬂammatorydiseasessuch
as sepsis, it appears difﬁcult to translate
successful animal studies into clinical
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sapplications. For instance, although neutralising
antibodies against endotoxin (Ref. 24) or
cytokines (e.g. TNF) (Refs 17, 140) are protective
in animal models of endotoxaemia or
bacteraemia, these agents failed in sepsis
clinical trials (Refs 141, 142, 143). This failure
partly reﬂects the complexity of the underlying
pathogenic mechanisms of sepsis and the
heterogeneity of the patient population (Refs 2,
144). It may also be attributable to pitfalls in the
selection of (1) feasible therapeutic targets or
drugs, (2) optimal doses and timing of drugs,
and (3) nonrealistic clinical outcome measures
(such as mortality rates) (Refs 2, 144).
Nevertheless, the investigation of pathogenic
cytokines in animal models of diseases has led
to the development of anti-TNF therapy for
patients with debilitating chronic inﬂammatory
diseases, such as rheumatoid arthritis (Ref. 145).
Consequently, a chimaeric anti-TNF monoclonal
antibody (inﬂiximab) and a soluble TNF-
receptor–Fc fusion protein (sTNF-R–Fc;
etanercept) have been approved by regulatory
authorities in the USA and Europe for treating
rheumatoid arthritis. Since pro-inﬂammatory
cytokines are indeed pathogenic in human
inﬂammatory diseases (such as rheumatoid
arthritis), it is necessary to continue the search
for clinically feasible therapeutic targets and
drugs for other inﬂammatory diseases (such as
sepsis).
Will HMGB1 ever become a clinically feasible
therapeutic target for human sepsis? We cannot
answer this question until HMGB1-neutralising
Steroid-like tanshinones and water-soluble derivatives
Expert Reviews in Molecular Medicine © 2008 Cambridge University Press
Tanshinone I
(TSN I)
(C18H12O3;
MW = 276.3)
O
O
O
CH3
CH3
CH3
CH3
CH3
Cryptotanshinone
(C-TSN)
(C19H20O3;
MW = 296.4)
CH3
CH3 H3C
O
O
O
Tanshinone IIA
(TSN IIA)
(C19H18O3;
MW = 294.3)
CH3
CH3 H3C
O
O
O
Tanshinone IIA sodium sulphonate
(TSN IIA-SS)
(C19H17O6Na;
MW = 396.4)
CH3
CH3 H3C
O
O
O SO3Na
Dexamethasone
(C22H29FO5)
Cortisone
(C21H28O5)
O
HO
F
OH
OH
O
O
O
OH
O
OH
H3C
CH3
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santibodies have been tested for efﬁcacy in large
clinical trials. Although HMGB1 appears to be a
feasible therapeutic target for experimental
sepsis (Refs 96, 146, 147), its levels in
unfractionated crude serum of septic patients
did not correlated well with disease severity
(Refs 148, 149). Upon separation of serum
proteins by ultraﬁltration through membrane
with a deﬁned molecular weight cut-off
(100 kDa), a 30 kDa HMGB1 band was detected
(by western blotting analysis) in both low
(,100 kDa) and high (.100 kDa) molecular
weight serum fractions of many septic patients.
Furthermore, HMGB1 levels in the low
(,100 kDa) serum fraction were signiﬁcantly
higher in septic patients who died of sepsis
than those who survived (Ref. 51). This
observation suggested a possibility that
HMGB1 may interact with other serum
componentstoformlarge(.100 kDa)complexes.
Indeed, many exogenous bacterial products
(such as endotoxin or CpG-DNA) (Refs 52, 71,
72) or endogenous proteins (such as human
thrombomodulin, IgG1 or IL-1) (Refs 115, 150)
may physically interact with HMGB1 to form
various complexes. It is not yet known how
these and as yet unidentiﬁed HMGB1-binding
molecules affect the biological activities, or
immunodetection, of HMGB1 in septic patients
(Refs 115, 148). In addition, chemical
modiﬁcations may similarly affect the biological
activities of HMGB1. For instance, a recent
study indicated that reactive oxygen species
(ROS) may oxidise HMGB1 to form an
intramolecular disulphide bond between the
thiol group of Cys106 and Cys23 or Cys45, and
consequently abolish HMGB1-mediated
immunostimulatory activities (Ref. 151).
Because Cys106 is located within the 18-amino-
acid cytokine domain of HMGB1 B box, it
will be important to investigate whether
oxidisation similarly affects biological activities
of HMGB1 in future studies.
Will any speciﬁc HMGB1 inhibitor ever become
a therapeutic agent for human sepsis? One of the
most selective HMGB1 inhibitors, TSN IIA-SS,
has already been used in China as a medicine
for patients with cardiovascular disorders
(Ref. 138). Even in septic animals, TSN IIA-SS
reduced total peripheral vascular resistance, and
yet increased cardiac stroke volume and cardiac
output (Ref. 135). Because HMGB1 may function
as a myocardial depressant factor by reducing
contractility of cardiac myocytes (Ref. 152), it is
plausible that TSN IIA-SS improves
cardiovascular function partly by attenuating
HMGB1 release. The dual effects of TSN IIA-SS
in attenuating late inﬂammatory response and
improving cardiovascular function make it a
promising therapeutic agent for sepsis.
Conclusions and perspectives
The ubiquitous nuclear protein HMGB1 is
released by activated macrophages/monocytes,
and functions as a late mediator of
experimental sepsis. First, circulating HMGB1
levels are elevated in a delayed fashion in
endotoxaemic and septic animals. Second,
administration of exogenous HMGB1 to mice
induces fever, derangement of intestinal barrier
function, and tissue injury. Third,
administration of anti-HMGB1 antibodies or
inhibitors rescues mice from lethal experimental
sepsis even when the ﬁrst dose is given 24 h
after onset of sepsis. Taken together, these data
establish HMGB1 as a late mediator of
experimental sepsis with a wider therapeutic
window than early mediators such as TNF.
HMGB1-speciﬁc neutralising antibodies and
small-molecule inhibitors (such as tanshinone
IIA derivative) have been proven protective in
animal models of experimental sepsis.
Currently, the intricate mechanisms by which
various agents attenuate systemic HMGB1
release and protect against experimental sepsis
remain poorly understood. In addition, it is not
yet known whether a better protection could be
achieved by combinational therapy with several
anti-HMGB1 agents. It is thus important to
further explore the therapeutic potential of
these HMGB1-inhibiting agents in future studies.
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Further reading, resources and contacts
Chadwick, D.J. and Goode, J., eds (2007) Novartis Foundation Symposium 280: Sepsis – New Insights. New
Therapies, John Wiley & Sons, New York, USA
Sepsis.com provides more information about the signs, diagnosis and potential treatment for severe sepsis:
http://www.sepsis.com
Surviving sepsis.org promotes the Surviving Sepsis Campaign (SSC), an initiative to improve the management,
diagnosis and treatment of sepsis:
http://www.survivingsepsis.org
MDidea.com provides a detailed description about potential use of Danshen and components (Tanshinone IIA)
in the treatment of various inﬂammatory ailments:
http://www.mdidea.com/products/herbextract/danshen/data.html
Features associated with this article
Figures
Figure 1. A microbial infection can trigger a local or systemic inﬂammatory response.
Figure 2. Extracellular HMGB1 functions as an alarmin signal.
Figure 3. Early versus late mediators of septic lethality.
Figure 4. Steroid-like tanshinones and water-soluble derivatives.
Tables
Table 1. Current available therapies for sepsis.
Table 2. Potential therapeutic agents for experimental sepsis.
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